低分子肝素与灯盏花素治疗原发性肾病综合征的临床研究

目的:研究低分子肝素与灯盏花素联合治疗原发性肾病综合征的临床疗效及不良反应.方法:将58例原发性肾病综合征患者,随机分为治疗组(30例)和对照组(28例).两组均予以限盐、低脂、优质蛋白饮食、利尿、降血压及糖皮质激素等常规基本治疗.治疗组加予低分子肝素与灯盏花素治疗2周,4周后比较两组治疗前后尿量、体重、尿蛋白、血清白蛋白、血脂、肾功能和凝血功能等变化,以及病情缓解情况.结果:尿量增加,体重减轻,尿蛋白与血脂下降、血清白蛋白升高和凝血功能改善,治疗组更为明显(P＜0.05).肾功能变化无显著差异(P＞0.05).治疗组完全缓解率和总有效率分别为40%和83.3%,显著高于对照组的30%和46.4%(P＜0.05),未发现明显不良反应.结论:在常规治疗基础上低分子肝素与灯盏花素联合治疗原发性肾病综合征是一种有效方法.

Clinical study of low molecular weight heparin and breviscapine on patients of primary nephritic

Objective:To study the therapeutic effect and side effect of coadministration of low molecular weight heparin(LMWH) and breviscapine on primary nephrotic syndrome(PNS).Methods:58 contemporaneous inpatients of PNS were divided into two groups randomly,therapeutic group(30 samples) and control group(28 samples),each group adopt conventional therapy,includes salt restriction,low fat diet,good protein diet,diuresis,blood pressure reduced,glucocorticosteroid et al.The therapeutic group coadministration LMWH and breviscapine for two weeks additionally,after four weeks comparied their changes in weight,urine volume,urine protein,serum albumin,blood fat,renal function ,blood coagulation function et al by pre-treatment and post-treatment.Results:Including urine volume increased,weight losed,urine protein and blood fat reduced,the serum albumin inceased,blood coagulation function improved,the therapeutic group was significant than that the control group(P<0.05),but there was no significant difference of changes in renal function between these two group(P>0.05);The complete remission rate and total effective rate is 40% and 83.3% in therapeutic group respectively,it is 30% and 46.4% in control group correspondingly,there is significant difference between these two group(P<0.05).and had no obvious side effect.Conclusion:It's an effectively therapeutic method to coadministration LMWH and breviscapine on PNS,based on the conventional therapy.